Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 8/20 | 0.54 |
| ▸ | MMP13 | P45452 | 5/20 | 0.54 |
| ▸ | MMP3 | P08254 | 4/20 | 0.54 |
| ▸ | MMP12 | P39900 | 3/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445437 | 1.00 | MMP8 (0.54) | MMP8MMP13MMP3MMP12FKBP1A | |
| SCHEMBL5444979 | 1.00 | MMP8 (0.54) | MMP8MMP13MMP3MMP12FKBP1A | |
| SCHEMBL5445135 | 0.93 | MMP8 (0.51) | MMP8MMP13MMP3MMP12FKBP1A | |
| SCHEMBL5437023 | 0.93 | MMP8 (0.51) | MMP8MMP13MMP3MMP12FKBP1A | |
| SCHEMBL5437350 | 0.93 | MMP8 (0.51) | MMP8MMP13MMP3MMP12FKBP1A | |
| SCHEMBL5164001 | 0.89 | MMP8 (0.52) | MMP8MMP13MMP3MMP12FKBP1A | |
| SCHEMBL5165977 | 0.89 | MMP8 (0.52) | MMP8MMP13MMP3MMP12FKBP1A | |
| SCHEMBL5433263 | 0.85 | MMP8 (0.43) | MMP8MMP13MMP3MMP12MMP1 | |
| SCHEMBL14427179 | 0.83 | MMP8 (0.62) | MMP8MMP13MMP3MMP12FKBP1A | |
| SCHEMBL5439636 | 0.83 | MMP8 (0.46) | MMP8MMP13MMP3MMP12FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-30 | — | — | US | claimed |
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | MMP9, MMP2, MMP3 | MMP8 18/4885MMP13 17/4885MMP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.